Eucalyptus: Business Description and Overview
Eucalyptus is a Sydney‑based direct‑to‑consumer telehealth company that operates several targeted digital health clinics. Each clinic focuses on a specific health area that is often underserved in traditional care. Its brands include Pilot for men’s health, Juniper for medical weight management, Kin for reproductive health, and Software for online dermatology. Each clinic uses a vertically integrated care model. This model combines online assessments, virtual doctor consultations, electronic prescriptions, and ongoing support such as coaching and treatment monitoring. Patients receive care through coordinated clinical and pharmacy workflows, which creates a seamless digital health experience.
Eucalyptus was founded in 2019 by Tim Doyle, Charlie Gearside, Benny Kleist, and Alexey Mitko. The company expanded rapidly by addressing conditions with high demand and low convenience in conventional healthcare. It now operates across Australia, the United Kingdom, Germany, Japan, and Canada, reflecting its strategy to build a global digital health platform.
Its weight‑management clinic, Juniper, also helped the company grow internationally due to rising global demand for GLP‑1‑based programs.
The Deal Structure
Hims & Hers’ acquisition of Eucalyptus is valued at up to US$1.15 billion. The transaction includes three major components: US$240 million in cash, US$710 million in guaranteed deferred payments, and up to US$200 million in performance‑based incentives tied to milestones. Hims & Hers may settle the deferred payments in cash or equity, providing flexibility for capital management. Funding for the deal will come mostly from the company’s current cash balance and operating cash flows from its U.S. business. Completion of the deal is expected in mid‑2026, pending regulatory approvals under New South Wales law.
Eucalyptus co‑founder and CEO Tim Doyle will join Hims & Hers as SVP of International. His stake, worth about US$115 million, highlights the scale of the outcome for founders and employees. Eucalyptus co‑founder and CEO Tim Doyle will join Hims & Hers as SVP of International. His stake, worth about US$115 million, highlights the scale of the outcome for founders and employees. This acquisition marks a major milestone for Eucalyptus, which raised several funding rounds before the exit. It also marks a shift in the global telehealth landscape as scaled platforms begin to consolidate.
Benefits of the Deal
Benefits of the Deal
Eucalyptus gives Hims & Hers an instant footprint in Australia, the UK, Germany, and Japan, with potential entry into Canada. This expansion occurs without lengthy setup processes, clinical licensing delays, or new logistical investments. The acquisition accelerates Hims & Hers’ global strategy by several years.
Vertical Integration
Eucalyptus operates multiple brands that use a fully integrated telehealth model. This includes digital intake, clinical review, e‑prescribing, and pharmacy fulfillment. Its structure matches the Hims & Hers model, allowing brands to scale across new regions with minimal friction. This alignment will support international brand portability and platform unification.
Broaden Revenues and, with that, the Customer Base
The acquisition adds about 775,000 customers and US$450 million in annualised revenue to Hims & Hers. This lift expands the company’s reach beyond its U.S. core and enhances efficiency across marketing, technology, and operational functions. Increased scale should improve margins while strengthening the company’s chronic care portfolio.
The acquisition is a major validation of its model and marks one of Australia’s largest digital‑health exits. It delivers substantial liquidity to founders, employees, and investors while giving the company access to Hims & Hers’ resources, capital, and global brand strength.
Disclaimer
The Investor Standard provides general information for education and research only. It is NOT personal advice, a recommendation, or an offer to buy/sell any security. This content has been prepared without taking into account your objectives, financial situation or needs. Past performance is not indicative of future results. Before acting on any information, consider its appropriateness and seek independent advice from a licensed financial adviser.